Investors look for Pfizer, Allergan, Mylan, Baxalta and others to address big questions at JP Morgan conference

Eric Palmer There are big questions facing some of pharma's key players this year, like whether the Pfizer and Allergan deal will get done and why Allergan thinks that is its best ...

Pfizer, Merck KGaA launch two more PhIII trials for avelumab

John Carroll The companies say that these two Phase III studies bring the late-stage program up to 6 studies, meeting their goal for 2015. FierceBiotech News

Pfizer nabs speedy FDA review for new use of lung cancer med Xalkori

Carly Helfand Pfizer's Xalkori is already used to treat patients with metastatic non-small cell lung cancer whose tumors are ALK-positive. But now it's on its way to snagging ...

Allergan CEO Saunders could cash out Pfizer deal with $187M, Bloomberg figures

Eric Palmer Even if Brent Saunders does not get the CEO role at Pfizer as a condition of Allergan agreeing to a buyout, which is reportedly being demanded, he will still get ...

Pfizer and Allergan wend toward a $150B merger, reports say

Tracy Staton Pfizer and Allergan are coming down to the wire on a merger that would be the biggest pharma deal ever. The all-stock transaction would be worth up to $ 150 billion, at ...

Pfizer responds to FiercePharma

Alok Saboo Tracy Staton wrote an article on Thursday, based on a piece in Forbes. Pfizer took exception to our article and sent a statement. FiercePharma News

Trial set for Pfizer in Protonix Medicaid rebate case it inherited

Eric Palmer A federal judge's inclination means Pfizer could remain in the line of fire to pay out more than $ 2 billion. That is the potential liability Pfizer faces for a federal ...

China slaps Pfizer with $500,000 in Viagra penalties for pharmacy tie-up

Emily Wasserman Pfizer has no problem keeping sales for Viagra flying high in China, where brand awareness campaigns and changing attitudes toward sex have given it a sizable hold on ...

Matchmaking investors pick Biogen, Pfizer as fave Allergan deal partners

Carly Helfand Who should serial buyer Allergan pick up next? It's the question on the minds of many industry watchers–including Evercore ISI analyst Umer Raffat, who ...

With $300M spent on potential split, Pfizer CEO now ‘biased’ toward branded M&A

Tracy Staton Now that Hospira's in the bag, Pfizer execs have less of an appetite for M&A in their Established Products unit. That $ 16 billion deal gives Pfizer added heft ...

Pfizer in quick succession turns aside second lawsuit alleging Zoloft birth defects ties

Eric Palmer Just weeks after winning the first case to go to trial that accused Pfizer of hiding birth defect risks for the children of women who took the antidepressant Zoloft during ...

Pfizer could buy GSK, but would Shire or Perrigo offer better targets?

Eric Palmer The speculation is building this week that Pfizer will either attempt another megadeal with GlaxoSmithKline or another run on AstraZeneca. Either would cut Pfizer's ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS